Clinuvel Pharmaceuticals Ltd
- Country
- 🇦🇺Australia
- Ownership
- -
- Employees
- 16
- Market Cap
- $473M
- Introduction
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.
Clinuvel Advances Phase III Trial for Vitiligo Treatment with SCENESSE®, Recruiting Over 200 Patients
Clinuvel Pharmaceuticals has successfully completed recruitment of more than 200 patients across North America, Africa, and Europe for its Phase III trial of SCENESSE® in vitiligo treatment.
Clinuvel Seeks EMA Approval for Increased SCENESSE Dosage in Europe
Clinuvel is in discussions with the EMA to increase the maximum annual dosage of SCENESSE for erythropoietic protoporphyria (EPP) patients from four to six doses.
Disc Medicine's Bitopertin Poised for Potential Accelerated FDA Approval in Erythropoietic Protoporphyria
Disc Medicine's bitopertin may receive accelerated FDA approval for erythropoietic protoporphyria (EPP) treatment based on existing clinical data.
Patient-Researcher's Journey Leads to Breakthrough Treatment for Rare Light Sensitivity Disorder
Dr. Jasmin Barman-Aksözen's personal experience with erythropoietic protoporphyria (EPP) led her to contribute to the development and approval of Scenesse, the first treatment for this rare genetic disorder.